The complexity of antibody-dependent enhancement of dengue virus infection

Viruses

Volumn 2, Issue 12, 2010, Pages 2649-2662

  Guzman, Maria G ^a   Vazquez, Susana ^a  

^a PAHO/WHO Collaborating Center for the Study of Dengue and its Vector   (Cuba)

Author keywords

ADE; Cleavage; Dengue; Dengue hemorrhagic fever; Neutralization; Prm

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; M PROTEIN; NEUTRALIZING ANTIBODY; PRM ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY RESPONSE; ARTICLE; CROSS REACTION; DENGUE; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; SECONDARY INFECTION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS PATHOGENESIS; VIRUS TRANSFORMATION;

DENGUE VIRUS;

EID: 79952171611     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2122649     Document Type: Article

References (96)

1. Dejnirattisai, W.; Jumnainsong, A.; Onsirisakul, N.; Fitton, P.; Vasanawathana, S.; Limpitikul, W.; Puttikhunt, C.; Edwards, C.; Duangchinda, T.; Supasa, S.; et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328, 745-748.
2. Guzman, M.G.; Kouri, G. Dengue: An update. Lancet Infect. Dis. 2002, 2, 33-42.
3. Gubler, D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 2002, 10, 100-103.
4. Beasley, D.W.C.; Barrett, A.D.T. The Infectious Agent. In Dengue; Pasvol, G., Hoffman, S.L., Eds.; Imperial College Press: Covent Garden, London, UK, 2008; Volume 5, pp. 29-73.
5. Guirakhoo, F.; Heinz, F.X.; Mandl, C.W.; Holzmann, H.; Kunz, C. Fusion activity of flaviviruses: Comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J. Gen. Virol. 1991, 72, 1323-1330.
6. Putnak, R.; Feighny, R.; Burrous, J.; Cochran, M.; Hackett, C.; Smith, G.; Hoke, C. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. Am. J. Trop. Med. Hyg. 1991, 45, 159-167.
7. Crill, W.D.; Roehrig, J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 2001, 75, 7769-7773.
8. Modis, Y.; Ogata, S.; Clements, D.; Harrison, S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 6986-6991.
9. Mandl, C.W.; Guirakhoo, F.; Holzmann, H.; Heinz, F.X.; Kunz, C. Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model. J. Virol. 1989, 63, 564-571.
10. Rey, F.A.; Heinz, F.X.; Mandl, C.; Kunz, C.; Harrison, S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995, 375, 291-298.
11. Roehrig, J.T.; Bolin, R.A.; Kelly, R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998, 246, 317-328.
12. Guirakhoo, F.; Bolin, R.A.; Roehrig, J.T. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology 1992, 191, 921-931.
13. Lindenbach, B.D.; Rice, C.M. Flaviviridae: The Viruses and Their Replication. In Fields Virology, Knippe, D.M., Howley, P.M.; Lippincott Willians & Wilkins: Philadelphia, USA, 2001; Volume 1, pp. 991-1042.
14. Thomas, G. Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol. 2002, 10, 753-766.
15. Zybert, I.A.; van der Ende-Metselaar, H.; Wilschut, J.; Smit, J.M. Functional importance of dengue virus maturation: Infectious properties of immature virions. J. Gen. Virol. 2008, 89, 3047-3051.
16. Elshuber, S.; Mandl, C.W. Resuscitating mutations in a furin cleavage-deficient mutant of the flavivirus tick-borne encephalitis virus. J. Virol. 2005, 79, 11813-11823.
17. Heinz, F.X.; Stiasny, K.; Puschner Auer, G.; Holzmann, H.; Allison, S.L.; Mandl, C.W.; Kunz, C. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 1994, 198, 109-117.
18. Sittisombut, N.; Keelapang, P.; Malasit, P. Functional role of prM glycoprotein in dengue virus replication. In Molecular Biology of the Flavivirus, Kalitzky, M., Borowski, P.; Horizon Bioscience: Norfolk, UK, 2006; p. 170.
19. WHO. Clinical Diagnosis. In Dengue Hemorrhagic Fever. Diagnosis, treatment, prevention and control, 2nd ed.; TDR/WHO; Geneva, Switzerland, 1997; pp. 1-84.
20. WHO. Strengthening implementation of the global strategy for dengue/dengue hemorrhagic fever prevention and control. Geneva, Switzerland, 1999; pp. 1-19.
21. Sabin, A.B. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1952, 1, 30-50.
22. Halstead, S.B. Etiologies of the experimental dengues of Siler and Simmons. Am. J. Trop. Med. Hyg. 1974, 23, 974-982.
23. Vaughn, D.W.; Scherer, J.M.; Sun, W. Resistance to infection. In Dengue; Pasvol, G., Hoffman, S.L., Eds.; Imperial College Press: Covent Garden, London, UK, 2008; Volume 5, pp. 123-169.
24. Guzman, M.G.; Alvarez, M.; Rodriguez-Roche, R.; Bernardo, L.; Montes, T.; Vazquez, S.; Morier, L.; Alvarez, A.; Gould, E.A.; Kouri, G.; et al. Neutralizing antibodies after infection with dengue 1 virus. Emerg. Infect. Dis. 2007, 13, 282-286.
25. Halstead, S.B. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J. Biol. Med. 1970, 42, 350-362.
26. Halstead, S.B.; Nimmannitya, S.; Cohen, S.N. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med. 1970, 42, 311-328.
27. Halstead, S.B. Immune enhancement of viral infection. Prog. Allergy 1982, 31, 301-364.
28. Kouri, G.P.; Guzman, M.G.; Bravo, J.R.; Triana, C. Dengue haemorrhagic fever/dengue shock syndrome: Lessons from the Cuban epidemic, 1981. Bull. World Health Organ. 1989, 67, 375-380.
29. Guzman, M.G.; Kouri, G.; Martinez, E.; Bravo, J.; Riveron, R.; Soler, M.; Vazquez, S.; Morier, L. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull. Pan. Am. Health Organ. 1987, 21, 270-279.
30. Diaz, A.; Kouri, G.; Guzman, M.G.; Lobaina, L.; Bravo, J.; Ruiz, A.; Ramos, A.; Martinez, R. Description of the clinical picture of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) in adults. Bull. Pan. Am. Health Organ. 1988, 22, 133-144.
31. Guzman, M.G.; Kouri, G.; Valdes, L.; Bravo, J.; Alvarez, M.; Vazquez, S.; Delgado, I.; Halstead, S.B. Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am. J. Epidemiol. 2000, 152, 793-799; discussion 804.
32. Valdes, L.; Guzman, M.G.; Kouri, G.; Delgado, J.; Carbonell, I.; Cabrera, M.V.; Rosario, D.; Vazquez, S. [Epidemiology of dengue and hemorrhagic dengue in Santiago, Cuba 1997]. Rev. Panam. Salud Publica 1999, 6, 16-25.
33. Kouri, G.; Guzman, M.G.; Valdes, L.; Carbonel, I.; del Rosario, D.; Vazquez, S.; Laferte, J.; Delgado, J.; Cabrera, M.V. Reemergence of dengue in Cuba: A 1997 epidemic in Santiago de Cuba. Emerg. Infect. Dis. 1998, 4, 89-92.
34. Pelaez, O.; Guzmán, M.G.; Kourí, G.; Pérez, R.; Martín, J.L.S.; Vázquez, S.; Rosario, D.; Mora, R.; Quintana, I.; Bisset, J.; et al. Dengue 3 epidemic in Havana, 2001. Emerg. Infect. Dis. 2004, 10, 219-222.
35. Gonzalez, D.; Castro, O.; Perez, J.; Martinez, E.; Vazquez, S.; Rosario, D.; Cancio, R.; Guzman, M.G. Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001-2002. Int. J. Infect. Dis. 2005, 9, 280-285.
36. Ghiasi, H.; Perng, G.C.; Nesburn, A.; Wechsler, S. Antibody-dependent enhancement of HSV-1 infection by anti-gK sera. Virus Res. 2000, 68, 137-144.
37. Girn, J.; Kavoosi, M.; Chantler, J. Enhancement of coxsackievirus B3 infection by antibody to a different coxsackievirus strain. J. Gen. Virol. 2002, 83, 351-358.
38. Hober, D.; Chehadeh, W.; Bouzidi, A.; Wattré, P. Antibody-dependent enhancement of coxsackievirus B4 infectivity of human peripheral blood mononuclear cells results in increased interferon-alpha synthesis. J. Infect. Dis. 2001, 184, 1098-1108.
39. Halstead, S.B. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 1979, 140, 527-533.
40. Goncalvez, A.P.; Engle, R.E.; St Claire, M.; Purcell, R.H.; Lai, C.J. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 9422-9427.
41. Kliks, S.C.; Nimmanitya, S.; Nisalak, A.; Burke, D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 1988, 38, 411-419.
42. Kliks, S.C.; Nisalak, A.; Brandt, W.E.; Wahl, L.; Burke, D.S. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 1989, 40, 444-451.
43. Guzman, M.G.; Kouri, G.; Valdes, L.; Bravo, J.; Vazquez, S.; Halstead, S.B. Enhanced severity of secondary dengue-2 infections: Death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud Publica 2002, 11, 223-227.
44. Guzman, M.G.; Kouri, G. Dengue haemorrhagic fever integral hypothesis: Confirming observations, 1987-2007. Trans. R. Soc. Trop. Med. Hyg. 2008, 102, 522-523.
45. Alvarez, M.; Rodriguez-Roche, R.; Bernardo, L.; Vazquez, S.; Morier, L.; Gonzalez, D.; Castro, O.; Kouri, G.; Halstead, S.B.; Guzman, M.G. Dengue Hemorrhagic Fever Caused by Sequential Dengue 1-3 Virus Infections over a Long Time Interval: Havana Epidemic, 2001-2002. Am. J. Trop. Med. Hyg. 2006, 75, 1113-1117.
46. Gollins, S.W.; Porterfield, J.S. Flavivirus infection enhancement in macrophages: Radioactive and biological studies on the effect of antibody on viral fate. J. Gen. Virol. 1984, 65, 1261-1272.
47. Gollins, S.W.; Porterfield, J.S. Flavivirus infection enhancement in macrophages: An electron microscopic study of viral cellular entry. J. Gen. Virol. 1985, 66, 1969-1982.
48. Halstead, S.B. Pathophysiology. In Dengue; Pasvol, G., Hoffman, S.L., Eds.; Imperial College Press: Covent Garden, London, UK, 2008; Volume 5, pp. 285-326.
49. Stephenson, J.R. Understanding dengue pathogenesis: Implications for vaccine design. Bull. World Health Organ. 2005, 83, 308-314.
50. Vaughn, D.W.; Green, S.; Kalayanarooj, S.; Innis, B.L.; Nimmannitya, S.; Suntayakorn, S.; Endy, T.P.; Raengsakulrach, B.; Rothman, A.L.; Ennis, F.A.; et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 2000, 181, 2-9.
51. Libraty, D.H.; Young, P.R.; Pickering, D.; Endy, T.P.; Kalayanarooj, S.; Green, S.; Vaughn, D.W.; Nisalak, A.; Ennis, F.A.; Rothman, A.L. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J. Infect. Dis. 2002, 186, 1165-1168.
52. Wang, W.K.; Chao, D.Y.; Kao, C.L.; Wu, H.C.; Liu, Y.C.; Li, C.M.; Lin, S.C.; Ho, S.T.; Huang, J.H.; King, C.C. High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: Implications for pathogenesis. Virology 2003, 305, 330-338.
53. Cameron, B.; Galbraith, S.; Zhang, Y.; Davenport, T.; Vollmer-Conna, U.; Wakefield, D.; Hickie, I.; Dunsmuir, W.; Whistler, T.; Vernon, S.; et al. Gene expression correlates of postinfective fatigue syndrome after infectious mononucleosis. J. Infect. Dis. 2007, 1, 56-66.
54. Lidbury, B.A.; Mahalingam, S. Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J. Virol. 2000, 74, 8376-8381.
55. Chareonsirisuthigul, T.; Kalayanarooj, S.; Ubol, S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J. Gen. Virol. 2007, 88, 365-375.
56. Henchal, E.A.; McCown, J.M.; Burke, D.S.; Seguin, M.C.; Brandt, W.E. Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am. J. Trop. Med. Hyg. 1985, 34, 162-169.
57. Pierson, T.C.; Diamond, M.S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev. Mol. Med. 2008, 10, e12.
58. King, N.J.; Getts, D.R.; Getts, M.T.; Rana, S.; Shrestha, B.; Kesson, A.M. Immunopathology of flavivirus infections. Immunol. Cell Biol. 2007, 85, 33-42.
59. Kaufman, B.M.; Summers, P.L.; Dubois, D.R.; Cohen, W.H.; Gentry, M.K.; Timchak, R.L.; Burke, D.S.; Eckels, K.H. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 1989, 41, 576-580.
60. Pierson, T.C. Modeling Antibody-Enhanced Dengue Virus Infection and Disease in Mice: Protection or Pathogenesis? Cell Host Microbe 2007, 7, 85-86.
61. Roehrig, J.T.; Mathews, J.H.; Trent, D.W. Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies. Virology 1983, 128, 118-126.
62. Throsby, M.; Geuijen, C.; Goudsmit, J.; Bakker, A.Q.; Korimbocus, J.; Kramer, R.A.; Clijsters-van der Horst, M.; de Jong, M.; Jongeneelen, M.; Thijsse, S.; et al. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J. Virol. 2006, 80, 6982-6992.
63. Lok, S.M.; Kostyuchenko, V.; Nybakken, G.E.; Holdaway, H.A.; Battisti, A.J.; Sukupolvi-Petty, S.; Sedlak, D.; Fremont, D.H.; Chipman, P.R.; Roehrig, J.T.; et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 2008, 15, 312-317.
64. Schieffelin, J.S.; Costin, J.M.; Nicholson, C.O.; Orgeron, N.M.; Fontaine, K.A.; Isern, S.; Michael, S.F.; Robinson, J.E. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol. J. 2010, 7, 28.
65. Wahala, W.M.; Kraus, A.A.; Haymore, L.B.; Accavitti-Loper, M.A.; de Silva, A.M. Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody. Virology 2009, 392, 103-113.
66. Wahala, W.M.; Donaldson, E.F.; de Alwis, R.; Accavitti-Loper, M.A.; Baric, R.S.; de Silva, A.M. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog. 2010, 6, e1000821.
67. Blaney, J.E., Jr.; Matro, J.M.; Murphy, B.R.; Whitehead, S.S. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J. Virol. 2005, 79, 5516-5528.
68. Alvarez, M.; Pavon-Oro, A.; Rodriguez-Roche, R.; Bernardo, L.; Morier, L.; Sanchez, L.; Alvarez, A.M.; Guzman, M.G. Neutralizing antibody response variation against dengue 3 strains. J. Med. Virol. 2008, 80, 1783-1789.
69. Bray, M.; Lai, C.J. Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology 1991, 185, 505-508.
70. Falconar, A.K. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: Design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch. Virol. 1999, 144, 2313-2330.
71. Vazquez, S.; Guzman, M.G.; Guillen, G.; Chinea, G.; Perez, A.B.; Pupo, M.; Rodriguez, R.; Reyes, O.; Garay, H.E.; Delgado, I.; et al. Immune response to synthetic peptides of dengue prM protein. Vaccine 2002, 20, 1823-1830.
72. Randolph, V.B.; Winkler, G.; Stollar, V. Acidotropic-amines inhibit proteolytic processing of flavivirus prM protein. Virology 1990, 174, 450-458.
73. Huang, K.J.; Yang, Y.C.; Lin, Y.S.; Huang, J.H.; Liu, H.S.; Yeh, T.M.; Chen, S.H.; Liu, C.C.; Lei, H.Y. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J. Immunol. 2006, 176, 2825-2832.
74. Yu, I.M.; Zhang, W.; Holdaway, H.A.; Li, L.; Kostyuchenko, V.A.; Chipman, P.R.; Kuhn, R.J.; Rossmann, M.G.; Chen, J. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 2008, 319, 1834-1837.
75. Rodenhuis-Zybert, I.A.; van der Schaar, H.M.; da Silva Voorham, J.M.; van der Ende-Metselaar, H.; Lei, H.Y.; Wilschut, J.; Smit, J.M. Immature dengue virus: A veiled pathogen? PLoS Pathog. 2010, 6, e1000718.
76. Keelapang, P.; Sriburi, R.; Supasa, S.; Panyadee, N.; Songjaeng, A.; Jairungsri, A.; Puttikhunt, C.; Kasinrerk, W.; Malasit, P.; Sittisombut, N. Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses. J. Virol. 2004, 78, 2367-2381.
77. Behrens, S.E.; Isken, O. Cis-and Trans-acting Determinants of Flaviviridae Replication. In Molecular Biology of the Flavivirus, Kalitzky, M., Borowski, P., Eds.; Horizon Bioscience: Norfolk, UK, 2006; p. 101.
78. Lai, M.M. Cellular factors in the transcription and replication of RNA genomesÑ a parallet to DNA-dependent RNA transcription. Virology 1998, 244, 1-12.
79. Valdes, K.; Alvarez, M.; Pupo, M.; Vazquez, S.; Rodriguez, R.; Guzman, M.G. Human Dengue antibodies against structural and nonstructural proteins. Clin. Diagn. Lab. Immunol. 2000, 7, 856-857.
80. Churdboonchart, V.; Bhamarapravati, N.; Peampramprecha, S.; Sirinavin, S. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 1991, 44, 481-493.
81. Se-Thoe, S.Y.; Ng, M.M.; Ling, A.E. Retrospective study of Western blot profiles in immune sera of natural dengue virus infections. J. Med. Virol. 1999, 57, 322-330.
82. Cherrier, M.V.; Kaufmann, B.; Nybakken, G.E.; Lok, S.M.; Warren, J.T.; Chen, B.R.; Nelson, C.A.; Kostyuchenko, V.A.; Holdaway, H.A.; Chipman, P.R.; et al. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. Embo J. 2009, 28, 3269-3276.
83. Kouri, G.P.; Guzman, M.G.; Bravo, J.R. Why dengue haemorrhagic fever in Cuba? 2. An integral analysis. Trans. R. Soc. Trop. Med. Hyg. 1987, 81, 821-823.
84. Rico-Hesse, R. Dengue virus evolution and virulence models. Clin. Infect. Dis. 2007, 44, 1462-1466.
85. Halstead, S.B. Dengue. Lancet 2007, 370, 1644-1652.
86. Guzman, M.G.; Kouri, G.; Bravo, J.; Valdes, L.; Vazquez, S.; Halstead, S.B. Effect of age on outcome of secondary dengue 2 infections. Int. J. Infect. Dis. 2002, 6, 118-124.
87. Halstead, S.B.; Streit, T.G.; Lafontant, J.G.; Putvatana, R.; Russell, K.; Sun, W.; Kanesa-Thasan, N.; Hayes, C.G.; Watts, D.M. Haiti: Absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am. J. Trop. Med. Hyg. 2001, 65, 180-183.
88. Bravo, J.R.; Guzman, M.G.; Kouri, G.P. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans. R. Soc. Trop. Med. Hyg. 1987, 81, 816-820.
89. Sierra, B.; Alegre, R.; Perez, A.B.; Garcia, G.; Sturn-Ramirez, K.; Obasanjo, O.; Aguirre, E.; Alvarez, M.; Rodriguez-Roche, R.; Valdes, L.; et al. HLA-A, -B, -C, and -DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: Advantages of the Cuban population for HLA studies of dengue virus infection. Hum. Immunol. 2007, 68, 531-540.
90. Garcia, G.; Sierra, B.; Perez, A.B.; Aguirre, E.; Rosado, I.; Gonzalez, N.; Izquierdo, A.; Pupo, M.; Ruiz, A.; Diaz, D.; et al. Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcyRIIa polymorphism. Am. J. Trop. Med. Hyg. 2010, 82, 1153-1156.
91. Sierra, B.; Kouri, G.; Guzman, M.G. Race: A risk factor for dengue hemorrhagic fever. Arch. Virol. 2007, 152, 533-542.
92. Halstead, S.B. Overview and History. In Dengue; Pasvol, G., Hoffman, S.L., Eds.; Imperial College Press: Covent Garden, London, UK, 2008; Volume 5, pp. 1-28.
93. Yamanaka, A.; Kosugi, S.; Konishi, E. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J. Virol. 2008, 82, 927-937.
94. Balsitis, S.J.; Williams, K.L.; Lachica, R.; Flores, D.; Kyle, J.L.; Mehlhop, E.; Johnson, S.; Diamond, M.S.; Beatty, P.R.; Harris, E. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010, 6, e1000790.
95. Mehlhop, E.; Ansarah-Sobrinho, C.; Johnson, S.; Engle, M.; Fremont, D.H.; Pierson, T.C.; Diamond, M.S. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2007, 2, 417-426.
96. Boonnak, K.; Slike, B.M.; Burgess, T.H.; Mason, R.M.; Wu, S.J.; Sun, P.; Porter, K.; Rudiman, I.F.; Yuwono, D.; Puthavathana, P.; et al. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J. Virol. 2008, 82, 3939-3951.